Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15136855 | 1.00 | MEN1 (0.31) | MEN1LMNACYP3A4KMT2A | |
| SCHEMBL17145148 | 0.89 | MEN1 (0.31) | MEN1LMNACYP3A4KMT2A | |
| SCHEMBL15144342 | 0.89 | MEN1 (0.31) | MEN1LMNACYP3A4KMT2A | |
| SCHEMBL22410841 | 0.85 | NEU3 (0.32) | — | |
| SCHEMBL9277681 | 0.80 | LMNA (0.36) | MEN1LMNACYP3A4KMT2A | |
| SCHEMBL11897987 | 0.80 | LMNA (0.36) | MEN1LMNACYP3A4KMT2A | |
| SCHEMBL11897986 | 0.80 | LMNA (0.36) | MEN1LMNACYP3A4KMT2A | |
| SCHEMBL3644921 | 0.80 | LMNA (0.36) | MEN1LMNACYP3A4KMT2A | |
| SCHEMBL13839336 | 0.80 | — | — | |
| SCHEMBL15146953 | 0.76 | LMNA (0.35) | MEN1LMNACYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319639-B2 | Flow synthesis process for the production of oseltamivir | Nelson Mandela University (ZA) | 2025-06-03 | — | — | US | disclosed |
| CN-113677658-B | Flow synthesis method for producing oseltamivir | 纳尔逊·曼德拉大学 | 2024-12-10 | — | — | CN | disclosed |
| EP-3938343-B1 | FLOW SYNTHESIS PROCESS FOR THE PRODUCTION OF OSELTAMIVIR | NELSON MANDELA UNIV (ZA) | 2024-10-09 | — | — | EP | disclosed |
| US-20220144756-A1 | FLOW SYNTHESIS PROCESS FOR THE PRODUCTION OF OSELTAMIVIR | Nelson Mandela University (ZA) | 2022-05-12 | — | — | US | disclosed |
| US-7531687-B2 | Preparation of oseltamivir phosphate | ROCHE PALO ALTO LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20090076296-A1 | Preparation of oseltamivir phosphate | ROCHE PALO ALTO LLC | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144756-A1 | FLOW SYNTHESIS PROCESS FOR THE PRODUCTION OF OSELTAMIVIR | CYP3A5, UMPS, KHK | MEN1 4612/4885LMNA 4694/4885CYP3A4 14/4885 |
| US-12319639-B2 | Flow synthesis process for the production of oseltamivir | CYP3A5, UMPS, KHK | MEN1 4612/4885LMNA 4694/4885CYP3A4 14/4885 |
| US-20090076296-A1 | Preparation of oseltamivir phosphate | PIP5K1A, PIP4K2A, PPIP5K2 | MEN1 3912/4885LMNA 3760/4885CYP3A4 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.